Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

Roche Basel Switzerland

Roche preps new Kadcyla filings after phase 3 trial win

Says the drug significantly reduced IDFS in women with residual disease

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

- PMLiVE

A look ahead to key trial readouts at ESMO

New combinations and novel mechanisms on show

- PMLiVE

RET rivals Loxo and Blueprint face off with early-stage data

No clear winner between RET inhibitor rivals

- PMLiVE

Chinese biotech’s global ambitions

BeiGene aims to be the first home-grown big biopharma

- PMLiVE

Roche gets wider approval for haemophilia drug Hemlibra

Approved to treat bleeding episodes in patients without inhibitors

- PMLiVE

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

Roche Basel Switzerland

Roche drug hits the mark in spinal muscular atrophy studies

Data suggests Risdiplam could improve motor function

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links